Detection and clinical studies of HER-2 in gastric cancer
10.3760/cma.j.issn.1673-4203.2011.07.017
- VernacularTitle:HER-2基因在胃癌中的检测与临床研究进展
- Author:
Benli JIA
;
Ling XIANGMENG
;
Xin LIZHU
- Publication Type:Journal Article
- Keywords:
Gastric cancer;
Tratuzumab;
HER-2;
SISH
- From:
International Journal of Surgery
2011;38(7):487-491
- CountryChina
- Language:Chinese
-
Abstract:
Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor-2( HER-2). Recent studies found that Trastuzumab in combination with chemotherapy could improve the survival of patients with HER-2 positive advanced gastric. However, the use of techniques like immunohistochemistry, fluorescence in situ hybridization (FISH) in assessing HER-2 status of gastric cancer has many disadvantages, a new technique silver-enhanced in situ hybridization (SISH) is likely to be the reference standard for assessing HER-2 status of gastric cancer. This paper reviews the advance of the detection and clinical studies of HER-2 in gastric cancer.
